1Hofmeyer KA, Jeon H, Zang X. The PIH/PD-Ll CB7-HI) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion[J]. BioMed Res Internat , 2011. 2011:451694.
2Hamid 0, Robert C, Daud A, et al. Safety and tumor re?sponses with lambrolizumab (anti-Ple-D in melanoma[J]. N Engl J Med, 2013, 369: 134-144 .
3Topalian SL. Hodi FS, Brahmer JR, etal. Safety, activity, and immune correlates of anti-Plr- 1 antibody in cancer[J]. N Engl J Med , 2012, 366: 2443-2454.
4BrahmerJ, Reckamp KL, Baas P, et ol., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cane- er[J]. N Engl J Med, 2015, 373: 123-135.
5Rizvi NA, Mazieres J, Planchard D, etal. Activity and safe?ty of nivolumab, an anti-Plr-I immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small?cell lung cancer ( Check Mat e 063): a phase 2, single-arm trial [J]. Lancet Oncol , 2015, 16: 257-265.
6Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J]. N Engl J Med, 2015, 373: 1627-1639.
7Garon EB, Rizvi N A, Hui R, et al . Pembrolizumab for the treatment of non-small-cell lung cancer [J]. N Eng J Med, 2016,16: 397-406.
8Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, P~Ll-positive, advanced non-small-cell lung cancer C KEYNOTE-O 1 0): a randomised controlled trial[J]. Lancet, 2016, 387: 1540-1550.
9Herbst RS, Soria JC, Kowanetz M, et al. Predictive corre?lates of response to the anti-Pl.r-Ll antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515: 563-567.
10McDermott J, Jimeno A. Pembrolizumab: PD-I inhibition as a therapeutic strategy in cancer[J]. Drug Today, 2015, 51: 7-20.
